134 related articles for article (PubMed ID: 28891081)
1. Improvement of the initial stage of interstitial lung disease during psoriasis treatment with secukinumab.
Miyachi H; Nakamura Y; Nakamura Y; Matsue H
J Dermatol; 2017 Dec; 44(12):e328-e329. PubMed ID: 28891081
[No Abstract] [Full Text] [Related]
2. Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris.
Kajihara I; Yamada-Kanazawa S; Maeda-Otsuka S; Jinnin M; Akaike K; Ihn H
J Dermatol; 2017 Dec; 44(12):e322-e323. PubMed ID: 28771789
[No Abstract] [Full Text] [Related]
3. Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris.
Hayashi M; Igarashi A; Okamura K; Suzuki T
Br J Dermatol; 2019 Mar; 180(3):684-685. PubMed ID: 30430554
[No Abstract] [Full Text] [Related]
4. Respiratory failure due to infliximab induced interstitial lung disease.
Kakavas S; Balis E; Lazarou V; Kouvela M; Tatsis G
Heart Lung; 2013; 42(6):480-2. PubMed ID: 23969008
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis-associated interstitial pneumonia.
Hara H; Kuwano K; Kawamoto H; Nakagawa H
Eur J Dermatol; 2018 Jun; 28(3):395-396. PubMed ID: 29521628
[No Abstract] [Full Text] [Related]
6. Ixekizumab-induced Interstitial Lung Disease.
Ahmed A; Khanna P; Al Omari O; Jani C; Patel D; Singh H; Schiffman R
Am J Ther; 2024 May-Jun 01; 31(3):e315-e318. PubMed ID: 37418343
[No Abstract] [Full Text] [Related]
7. Serum KL-6 levels in Japanese patients with psoriasis treated with secukinumab.
Kurita M; Kikuchi S; Umezawa Y; Asahina A; Nakagawa H; Yanaba K
J Dermatol; 2019 Apr; 46(4):e115-e116. PubMed ID: 30204267
[No Abstract] [Full Text] [Related]
8. Secukinumab for the treatment of residual psoriasis: a case series.
Malagoli P
J Dermatolog Treat; 2018; 29(sup1):12-13. PubMed ID: 30919723
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Chaouche-Teyara K
J Am Acad Dermatol; 2019 May; 80(5):1344-1352. PubMed ID: 30716404
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab shows significant efficacy in two patients with difficult-to-treat areas of psoriasis: a Greek experience.
Platsidaki E; Kostopoulos N; Marnelakis I; Panagakis P
Dermatol Online J; 2018 Mar; 24(3):. PubMed ID: 29634892
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.
Cannavò SP; Postorino E; Aragona E; Bartolotta A; Papaianni V; Guarneri C
J Dermatolog Treat; 2018; 29(sup1):9-11. PubMed ID: 30247938
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung abnormalities: ignotum per ignotius.
Antoniou KM; Tzilas V; Vasarmidi E; Symvoulakis EK; Tzouvelekis A; Bouros D
Lancet Respir Med; 2019 May; 7(5):376-378. PubMed ID: 30935882
[No Abstract] [Full Text] [Related]
15. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab efficacy in the treatment of nail psoriasis: a case series.
Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR
J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
[TBL] [Abstract][Full Text] [Related]
19. Complete response of secukinumab in palmoplantar psoriasis.
Rocamora V; Garcías-Ladaria J
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis.
Korman NJ; Sofen H; Fretzin S; Rich P; Zhao Y; Herrera V; Nyirady J; Williams N; Mordin M; Tyring S
J Dermatolog Treat; 2017 Aug; 28(5):384-389. PubMed ID: 27832717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
